Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer

Dear Colleagues, 

The epidermal growth factor receptor (EGFR) is a major contributor to tumor development and progression as well as an important therapeutic target. The EGFR and its ligands are often over-expressed in human carcinomas. Amplification of the EGFR gene, mutations within the EGFR tyrosine kinase domain and aberrant signaling are common in human epithelial malignancies where they impact tumor cell proliferation, plasticity, survival, localized tissue invasion and metastasis. The EGF/EGFR axis is also involved in drug resistance and pathologic cross-talk with other growth factor signaling pathways to promote inflammatory, angiogenic, fibrotic and mechanical changes in the tumor microenvironment, facilitating oncogenic behavior. EGFR transactivation by various cytokines and growth factors further underscore the complexity of engaged networks that dictate tumor cell phenotype and may shed light on the basis for the limited clinical utility of available EGFR inhibitors in halting cancer progression. The purpose of this Special Issue is to explore the expanding diversity of mechanisms that regulate EGFR activation and signaling in human neoplasms that may provide new opportunities for personalized anti-cancer therapy. We welcome submission of both review and original research articles for inclusion in this Special Issue by September 15, 2022

Dr. Paul J. Higgins
Dr. Rohan Samarakoon
Dr. Marzia Di Donato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.